Q2 2025 Baxter International Inc Earnings Call Transcript
Key Points
- Baxter International Inc (BAX) reported a 4% increase in second-quarter sales from continuing operations on a reported basis, with growth across all three segments.
- Adjusted earnings per share from continuing operations increased by 28% over the prior year, reaching $0.59.
- The sale of Vantive has been completed, creating a more agile and focused business structure.
- Baxter International Inc (BAX) has entered a strategic partnership with Vizient to ensure reliable access to IV fluids during supply disruptions.
- The company is optimistic about future opportunities to accelerate innovation and growth, with a focus on operational effectiveness and performance improvement.
- Second-quarter results came in at the low end of guidance ranges due to softness in demand for certain products within the Medical Products and Therapies and Pharmaceutical segments.
- The company has voluntarily paused shipments and installations of the Novum LVP infusion platform due to feedback from quality procedures and customer insights.
- Fluid conservation efforts by hospitals have impacted sales, with expectations that these efforts may not materially improve in the second half of the year.
- Adjusted gross margins from continuing operations decreased by 170 basis points compared to the prior year, primarily due to lower manufacturing volumes and an unfavorable product mix.
- Baxter International Inc (BAX) has reduced its full-year operational sales growth expectations from 4%-5% to 3%-4% due to potential downside risks associated with infusion pumps and fluid conservation.
Good morning, ladies and gentlemen, and welcome to Baxter International's second quarter 2025 earnings call. (Operator Instructions) As a reminder, this call is being recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. If you have any objections, please disconnect at this time.
I would now like to turn the call over to Ms. Clare Trachtman, Senior Vice President -- Chief Investor Relations Officer at Baxter International. Ms. Trachtman, you may begin.
Good morning, and welcome to our second quarter 2025 earnings conference call. Joining me today are Brent Shafer, Baxter's Chair and Interim Chief Executive Officer; Joel Grade, Baxter's Executive Vice President and Chief Financial Officer; and Heather Knight, Baxter's Executive Vice President and Chief Operating Officer. On the call this morning, we will be discussing Baxter's second quarter 2025 results, along with our financial outlook for the third quarter and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
